AP NEWS

Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference

November 8, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 8, 2018--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 27 th Annual Credit Suisse Healthcare Conference on Wednesday, November 14 th, 2018 at 2:15 p.m. Mountain Time (4:15 p.m. Eastern Time) at the Phoenician in Scottsdale, Arizona.

A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Our pipeline priorities for linaclotide include a Phase IIIb trial evaluating its efficacy and safety on multiple abdominal symptoms, including abdominal bloating, pain, and discomfort in adult patients with IBS-C, as well as research into a formulation of linaclotide designed to relieve pain across all IBS subtypes.

We are also advancing a pipeline of innovative product candidates in areas of significant unmet need, including persistent gastroesophageal reflux disease, diabetic nephropathy, heart failure with preserved ejection fraction and sickle cell disease. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181108005935/en/

CONTACT: Ironwood Pharmaceuticals, Inc.

Meredith Kaya, 617-374-5082

Vice President, Investor Relations and Corporate Communications

mkaya@ironwoodpharma.com

KEYWORD: UNITED STATES NORTH AMERICA ARIZONA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Ironwood Pharmaceuticals, Inc.

Copyright Business Wire 2018.

PUB: 11/08/2018 04:05 PM/DISC: 11/08/2018 04:05 PM

http://www.businesswire.com/news/home/20181108005935/en

AP RADIO
Update hourly